Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib

International Journal of Colorectal Disease

Volumn 25, Issue 7, 2010, Pages 795-804

  Voutsadakis, Ioannis A ^a   Patrikidou, Anna ^a   Tsapakidis, Konstantinos ^a   Karagiannaki, Aristea ^a   Hatzidaki, Eleana ^a   Stathakis, Nikolaos E ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Aspirin; Bortezomib; CaCo2; Cell lines; Colorectal cancer; Cyclooxygenase 2; HCT116; HT 29; Proteasome

Indexed keywords

ACETYLSALICYLIC ACID; AKT1 KINASE; BORTEZOMIB; CYCLOOXYGENASE 2; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P21; PROTEIN P27; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER INHIBITION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STRAIN CACO 2; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SURVIVAL; COLORECTAL CANCER; COLORIMETRY; CONTROLLED STUDY; CYTOPLASM; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

APOPTOSIS; ASPIRIN; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES;

EID: 77953289674     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-010-0939-0     Document Type: Article

References (49)

1. RA Gupta RN DuBois 2001 Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 Nat Rev Cancer 1 11 21 10.1038/35094017 1:STN:280:DC%2BD387mvVOhsA%3D%3D 11900248
2. JR Brown RN DuBois 2005 COX-2: a molecular target for colorectal cancer prevention J Clin Oncol 23 2840 2855 10.1200/JCO.2005.09.051 1:CAS:528:DC%2BD2MXktleqt7w%3D 15837998 (Pubitemid 46179475)
3. DH Wolf W Hilt 2004 The proteasome: a proteolytic nanomachine of cell regulation and waste disposal Biochim Biophys Acta 1695 19 31 10.1016/j.bbamcr.2004.10.007 1:CAS:528:DC%2BD2cXhtVantb%2FF 15571806 (Pubitemid 39574965)
4. A Mani EP Gelmann 2005 The ubiquitin-proteasome pathway and its role in cancer J Clin Oncol 23 4776 4789 10.1200/JCO.2005.05.081 1:CAS:528: DC%2BD2MXotFars7o%3D 16034054 (Pubitemid 46224082)
5. JB Almond GM Cohen 2002 The proteasome: a novel target for cancer chemotherapy Leukemia 16 433 443 10.1038/sj.leu.2402417 1:CAS:528: DC%2BD38XjvFGnur8%3D 11960320
6. X-M Sun M Butterworth M MacFarlane W Dubiel A Ciechanover GM Cohen 2004 Caspase activation inhibits proteasome function during apoptosis Mol Cell 14 81 93
7. C Adrain EM Creagh SP Cullen SJ Martin 2004 Caspase-dependent inactivation of proteasome function during programmed cell death in drosophila and man J Biol Chem 279 36923 36930 10.1074/jbc.M402638200 1:CAS:528: DC%2BD2cXmvFCmtrY%3D 15210720 (Pubitemid 39129042)
8. J Friedman D Xue 2004 To live or die by the sword: the regulation of apoptosis by the proteasome Dev Cell 7 460 461
9. PG Richardson T Hideshima KC Anderson 2003 Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers Cancer Control 10 361 369 14581890
10. CN Papandreou DD Daliani D Nix H Yang T Madden X Wang, et al. 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 2108 2121 10.1200/JCO.2004.02.106 1:CAS:528:DC%2BD2cXpsVWlsLc%3D 15169797 (Pubitemid 41095144)
11. C Aghajanian S Soignet DS Dizon CS Pien J Adams PJ Elliott, et al. 2002 A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2505 2511 1:CAS:528:DC%2BD38XmvVaiu7g%3D 12171876
12. C Aghajanian DS Dizon P Sabbatini JJ Raizer J Dupont DR Spriggs 2005 Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer J Clin Oncol 23 5943 5949 10.1200/JCO.2005.16.006 1:CAS:528:DC%2BD2MXhtVKgtbzE 16135465
13. L Levine 2004 Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells BMC Pharmacol 4 15 10.1186/1471-2210-4-15 15296516 (Pubitemid 40177099)
14. P Rockwell H Yuan R Magnusson 2000 Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE Arch Biochem Biophys 374 325 333
15. UR Mbonye C Yuan CE Harris RS Sidhu I Song T Arakawa WL Smith 2008 Two distinct pathways for cyclooxygenase-2 protein degradation J Biol Chem 283 8611 8623
16. IA Voutsadakis 2007 Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 J Cell Mol Med 11 252 285 10.1111/j.1582-4934.2007.00032.x 1:CAS:528:DC%2BD2sXmsFykurs%3D 17488476 (Pubitemid 46695694)
17. J-L Fischel P Formento G Milano 2005 Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors Br J Cancer 92 1063 1068 10.1038/sj.bjc.6602428 1:CAS:528:DC%2BD2MXisVyisbg%3D 15756277 (Pubitemid 40546670)
18. IA Voutsadakis 2008 The ubiquitin-proteasome system in colorectal cancer Biochim Biophys Acta 1782 800 808 1:CAS:528:DC%2BD1cXhsVCntbzO 18619533
19. RS Sandler S Halabi JA Baron S Budinger E Paskett R Keresztes, et al. 2003 A randomized trial of aspirin to prevent colorectal adenoma in patients with previous colorectal cancer N Engl J Med 348 883 890 10.1056/NEJMoa021633 1:CAS:528:DC%2BD3sXhvVOisbw%3D 12621132 (Pubitemid 36297996)
20. JA Baron BF Cole RS Sandler RW Haile D Ahnen R Bresalier, et al. 2003 A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 891 899 10.1056/NEJMoa021735 1:CAS:528:DC%2BD3sXhvVOitrw%3D 12621133 (Pubitemid 36297997)
21. MJ Thun SJ Henley C Patrono 2002 Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 252 266 1:CAS:528:DC%2BD38Xit1ygtb8%3D 11854387
22. HM Wang GY Zhang 2005 Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo World J Gastroenterol 11 340 343 1:CAS:528:DC%2BD2MXhs1ejsrw%3D 15637740
23. S Grösch I Tegeder E Niederberger L Bräutigam G Geisslinger 2001 COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib FASEB J 15 2742 2744 11606477
24. H-G Yu J-A Huang Y-N Yang H Huang H-S Luo J-P Yu, et al. 2002 The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells Eur J Clin Invest 32 838 846 10.1046/j.1365-2362.2002.01080.x 1:CAS:528:DC%2BD38Xpslelu7o%3D 12423325 (Pubitemid 35356936)
25. M-L Smith G Hawcroft MA Hull 2000 The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action Eur J Cancer 36 664 674 10.1016/S0959-8049(99)00333-0 1:CAS:528:DC%2BD3cXitVSnsL8%3D 10738133 (Pubitemid 30156854)
26. H Yin H Xu Y Zhao W Yang J Cheng Y Zhou 2006 Cyclooxygenase-independent effects of aspirin on HT-29 human colon cancer cells, revealed by oligonucleotide microarrays Biotechnol Lett 28 1263 1270 10.1007/s10529-006- 9084-9 1:CAS:528:DC%2BD28XmvFeisbo%3D 16819585 (Pubitemid 44078495)
27. MJ Yin Y Yamamoto RB Gaynor 1998 The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta Nature 396 77 80 10.1038/23948 1:CAS:528:DyaK1cXnsVSjur0%3D 9817203 (Pubitemid 28520452)
28. PL Rice J Kelloff H Sullivan LJ Driggers KS Beard S Kuwada, et al. 2003 Sulindac metabolites induce caspase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells Mol Cancer Ther 2 885 892 1:CAS:528:DC%2BD3sXotVShtLY%3D 14555707
29. LC Hsi SJ Baek TE Eling 2000 Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells Exp Cell Res 256 563 570 10.1006/excr.2000.4863 1:CAS:528:DC%2BD3cXisFelu7g%3D 10772828 (Pubitemid 30244214)
30. TE Crew DJE Elder C Paraskeva 2000 A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate Carcinogenesis 21 69 77 10.1093/carcin/21.1.69 1:CAS:528:DC%2BD3cXhtValtb0%3D 10607736
31. S Lev-Ari L Strier D Kazanov L Madar-Shapiro H Dvory-Sobol I Pinchuk, et al. 2005 Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells Clin Cancer Res 11 6738 6744 10.1158/1078-0432.CCR-05-0171 1:CAS:528:DC%2BD2MXhtVShsb3J 16166455 (Pubitemid 41339017)
32. A Montagnoli F Fiore E Eytan AC Carrano GF Draetta A Hershko M Pagano 1999 Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation Genes Dev 13 1181 1189
33. IM Chu L Hengst JM Slingerland 2008 The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 253 267 10.1038/nrc2347 1:CAS:528:DC%2BD1cXjsFCmsLw%3D 18354415 (Pubitemid 351430863)
34. P Dikshit M Chatterjee A Goswami A Mishra NR Jana 2006 Aspirin induces apoptosis through the inhibition of proteasome function J Biol Chem 281 29228 29235 10.1074/jbc.M602629200 1:CAS:528:DC%2BD28XpvFamsL0%3D 16880202 (Pubitemid 44507066)
35. J Bloom V Amador F Bartolini G DeMartino M Pagano 2003 Proteasome-mediated degradation of p21 via N-terminal ubiquitination Cell 115 71 82 10.1016/S0092-8674(03)00755-4 1:CAS:528:DC%2BD3sXotFSltLc%3D 14532004 (Pubitemid 37255319)
36. J Bloom M Pagano 2004 To be or not to be...ubiquitinated? Cell Cycle 3 138 140 1:CAS:528:DC%2BD2cXisFGnu7g%3D 14712075
37. F Chen D Chang M Goh SA Klibanov M Ljungman 2000 Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors Cell Growth Differ 11 239 246 1:CAS:528:DC%2BD3cXjvFajs7o%3D 10845424
38. JL Yu L May V Lhotak S Shahrzad S Shirasawa JI Weitz BL Coomber N Mackman JW Rak 2005 Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis Blood 105 1734 1741 10.1182/blood-2004-05-2042 1:CAS:528:DC%2BD2MXhsVCqu74%3D 15494427 (Pubitemid 40223697)
39. Kip1 deregulation in colorectal cancer Cancer 107 668 675 10.1002/cncr.22073 1:CAS:528:DC%2BD28XpsFGktLo%3D 16826582 (Pubitemid 44232659)
40. GV Thomas K Szigeti M Murphy G Draetta M Pagano M Loda 1998 Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases Am J Pathol 153 681 687 1:CAS:528:DyaK1cXmtFKntbg%3D 9736017
41. M Adachi KR Katsumura K Fujii S Kobayashi H Aoki M Matsuzaki 2003 Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells FEBS Lett 554 77 80 10.1016/S0014-5793(03)01109-8 1:CAS:528: DC%2BD3sXosVymu7o%3D 14596918 (Pubitemid 37324818)
42. NC Cheung MS Choy B Halliwell TS Teo BH Bay AY-W Lee, et al. 2004 Lactacystin-induced apoptosis of cultured mouse cortical neurons is associated with accumulation of PTEN in the detergent-resistant membrane fraction Cell Mol Life Sci 61 1926 1934 10.1007/s00018-004-4127-7 1:CAS:528:DC%2BD2cXnsVWgtLo%3D 15289934
43. MH Cardone N Roy HR Stennicke GS Salvesen TF Franken E Stanbridge, et al. 1998 Regulation of cell death protease caspase-9 by phosphorylation Science 282 1318 1321 10.1126/science.282.5392.1318 1:CAS:528:DyaK1cXnsFentLY%3D 9812896
44. ZJ Chen 2005 Ubiquitin signalling in the NF-κB pathway Nat Cell Biol 7 758 765 10.1038/ncb0805-758 1:CAS:528:DC%2BD2MXmvVCltb8%3D 16056267 (Pubitemid 41079044)
45. J Deng SA Miller H-Y Wang W Xia Y Wen BP Zhou Y Li, et al. 2002 β-catenin interacts with and inhibits NF-κB in human colon and breast cancer Cancer Cells 2 323 334 10.1016/S1535-6108(02)00154-X 1:CAS:528:DC%2BD38Xot1Gkt7Y%3D (Pubitemid 41043966)
46. C Qin R Burghardt R Smith M Wormke J Stewart S Safe 2003 Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells Cancer Res 63 958 964
47. L Scorrano SJ Korsmeyer 2003 Mechanisms of cytochrome c release by proapoptotic BCL-2 family members Biochem Biophys Res Commun 304 437 444 10.1016/S0006-291X(03)00615-6 1:CAS:528:DC%2BD3sXjt1Kisrw%3D 12729577 (Pubitemid 36506515)
48. HJ Choi HH Kim HS Lee GY Huh SY Seo JH Jeong, et al. 2003 Lactacystin augments the sulindac-induced apoptosis in HT-29 cells Apoptosis 8 301 305 10.1023/A:1023681007766 12766490 (Pubitemid 36749615)
49. T Minami M Adachi R Kawamura Y Zhang Y Shinomura K Imai 2005 Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity Clin Cancer Res 11 5248 5256 10.1158/1078-0432.CCR-05-0085 1:CAS:528:DC%2BD2MXmt12qurs%3D 16033843 (Pubitemid 41003713)